Dianthus Therapeutics Strengthens Market Position Thanks to Strong Study Data

Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing novel antibodies. At the center is the drug candidate DNTH103, which selectively targets the active form of the C1s protein, playing a central role in various autoimmune and inflammatory diseases. Through this approach, therapies aim to provide patients with greater safety, comfort, and flexibility, such as the possibility of subcutaneous self-administration. Potential application areas range from neuromuscular diseases like generalized Myasthenia Gravis to rare immunological...